Preston G C, Keene O N, Palmer J L
Glaxo Wellcome Research and Development, Greenford, Middlesex.
Anaesthesia. 1996 Sep;51(9):827-30. doi: 10.1111/j.1365-2044.1996.tb12610.x.
The objective of this study was to determine the effects of ondansetron on the pharmacokinetics of temazepam and on pharmacodynamics relevant to its use as oral premedication. Twenty-four healthy volunteers (12 of each sex) were administered the following oral treatments in a randomised, double-blind crossover design: temazepam 20 mg plus placebo; or temazepam 20 mg plus ondansetron 8 mg. Blood samples were taken for plasma temazepam assay at intervals up to 32 h after administration. In addition, a brief battery of psychomotor tests was administered 1 h prior to dosing and 1 and 4 h after dosing. Analysis of the derived pharmacokinetic parameters showed no differences between the treatments described above. Analysis of data from the dynamic measures likewise showed no difference between the treatments. It was concluded that the co-administration of ondansetron did not influence the pharmacokinetics or pharmacodynamic actions of temazepam.
本研究的目的是确定昂丹司琼对替马西泮药代动力学以及与其作为口服术前用药相关的药效学的影响。24名健康志愿者（男女各12名）按照随机、双盲交叉设计接受以下口服治疗：20毫克替马西泮加安慰剂；或20毫克替马西泮加8毫克昂丹司琼。给药后长达32小时内每隔一段时间采集血样用于血浆替马西泮测定。此外，在给药前1小时以及给药后1小时和4小时进行一组简短的精神运动测试。对得出的药代动力学参数进行分析表明上述治疗之间没有差异。对动态测量数据的分析同样表明治疗之间没有差异。得出的结论是，昂丹司琼与替马西泮合用不会影响替马西泮的药代动力学或药效学作用。
